Home » Stocks » PTPI

Petros Pharmaceuticals, Inc. (PTPI)

Stock Price: $3.75 USD -0.31 (-7.64%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 38.83M
Revenue (ttm) 15.58M
Net Income (ttm) -32.51M
Shares Out 1.71M
EPS (ttm) -19.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $3.75
Previous Close $4.06
Change ($) -0.31
Change (%) -7.64%
Day's Open 4.05
Day's Range 3.75 - 4.14
Day's Volume 100,591
52-Week Range 3.24 - 4.68

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 2 months ago

NEW YORK, Nov. 20, 2020 /PRNewswire/ -- Neurotrope, Inc. (NASDAQ: NTRP) ("Neurotrope" or the "Company") announced today that its Board of Directors has approved the conditional distribution an...

PRNewsWire - 3 months ago

NEW YORK and MANALAPAN TOWNSHIP, N.J., Sept. 30, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company focused o...

PRNewsWire - 8 months ago

NEW YORK and MANALAPAN TOWNSHIP, N.J., May 18, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company ("Metuchen"...

Benzinga - 1 year ago

Shares of thinly-traded microcap biopharma Neurotrope Inc (NASDAQ: NTRP) gap-opened sharply higher on above 50 times average volume following a corporate update from the company.

24/7 Wall Street - 1 year ago

It may be unusual to see a stock rise close to 100% without a corporate buyout, but in biotech and emerging pharmaceutical companies gains of that size can occur simply with a drug study updat...

Market Watch - 1 year ago

Shares of Neurotrope Inc. NTRP, -77.95% plummeted 79% on heavy volume Monday, to below the $1 mark for the first time in six years, after the biopharmaceutical company said its Alzheimer's dis...

Benzinga - 1 year ago

Shares of thinly-traded nano-cap biotech Neurotrope Inc (NASDAQ: NTRP) were plummeting Monday following an adverse clinical trial readout.

Zacks Investment Research - 1 year ago

Neurotrope has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Neurotrope (NTRP) stock based on the movements in the options market lately.

24/7 Wall Street - 1 year ago

The biotechnology sector is generally considered the most volatile and riskiest sector within all of healthcare.

Other stocks mentioned: AVXL, NTRP
24/7 Wall Street - 1 year ago

Neurotrope, Inc. may be a winner by default in the battle against Alzheimer’s disease after shares of Biogen Inc. suffered handily with the announcement that it and partner Eisei were halting ...

About PTPI

Petros Pharmaceuticals engages in identifying, acquiring, developing, and commercializing therapeutics for men's health issues. The company operates through two segments, Prescription Medications and Medical Devices. It focuses on erectile dysfunction, peyronie's disease, endothelial dysfunction, and prostate cancer; and hormone health, and products enhancing overall health and wellness in men. The company offers prescription medication, such as Stendra for the treatment of erectile dysfunction; and vacuum erection devices. Petros Pharmaceutica... [Read more...]

Industry
Biotechnology
Founded
2020
CEO
Dr. Charles S. Ryan J.D., Ph.D.
Employees
43
Stock Exchange
NASDAQ
Ticker Symbol
PTPI
Full Company Profile